Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
Brain metastasis from intrahepatic cholangiocarcinoma (iCCA) is extremely rare, and no standard therapeutic strategy has been established. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been widely studied in treating liver cancer. Combined immunotherapy and targeted the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382583/ https://www.ncbi.nlm.nih.gov/pubmed/35992782 http://dx.doi.org/10.3389/fonc.2022.911202 |
_version_ | 1784769313107869696 |
---|---|
author | Xie, Peiyi Guo, Lei Zhang, Bo Xu, Yongfeng Song, Qi Shi, Hongcheng Ye, Qinghai Li, Hui Xiao, Yongsheng |
author_facet | Xie, Peiyi Guo, Lei Zhang, Bo Xu, Yongfeng Song, Qi Shi, Hongcheng Ye, Qinghai Li, Hui Xiao, Yongsheng |
author_sort | Xie, Peiyi |
collection | PubMed |
description | Brain metastasis from intrahepatic cholangiocarcinoma (iCCA) is extremely rare, and no standard therapeutic strategy has been established. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been widely studied in treating liver cancer. Combined immunotherapy and targeted therapy are a promising approach for treating advanced iCCA. Despite that immune checkpoint inhibitor (ICI)-based neoadjuvant therapy on iCCA has shown a significant response rate and resection rate, few reports have shown the therapeutic efficacy of immunotherapy in treating brain metastasis from iCCA. Although PD-1 inhibitors such as pembrolizumab, nivolumab, or camrelizumab are increasingly applied in clinic practice to treat multiple malignancies, to the best of our knowledge, we report the first case of an iCCA patient with brain metastasis successfully treated with a combined immunotherapy and targeted therapy. The patient is a 54-year-old man with metastatic iCCA in brain treated though camrelizumab plus lenvatinib therapy with a complete response (CR). By the time of writing, he has had a progression-free survival of 17.5 months and did not experience any severe side effects related to this therapy. Camrelizumab plus lenvatinib therapy showed favorable efficacy and manageable toxicity for this patient with advanced iCCA and could be of interest for more prospective randomized trials to further verify the potential clinical benefits. |
format | Online Article Text |
id | pubmed-9382583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93825832022-08-18 Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review Xie, Peiyi Guo, Lei Zhang, Bo Xu, Yongfeng Song, Qi Shi, Hongcheng Ye, Qinghai Li, Hui Xiao, Yongsheng Front Oncol Oncology Brain metastasis from intrahepatic cholangiocarcinoma (iCCA) is extremely rare, and no standard therapeutic strategy has been established. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been widely studied in treating liver cancer. Combined immunotherapy and targeted therapy are a promising approach for treating advanced iCCA. Despite that immune checkpoint inhibitor (ICI)-based neoadjuvant therapy on iCCA has shown a significant response rate and resection rate, few reports have shown the therapeutic efficacy of immunotherapy in treating brain metastasis from iCCA. Although PD-1 inhibitors such as pembrolizumab, nivolumab, or camrelizumab are increasingly applied in clinic practice to treat multiple malignancies, to the best of our knowledge, we report the first case of an iCCA patient with brain metastasis successfully treated with a combined immunotherapy and targeted therapy. The patient is a 54-year-old man with metastatic iCCA in brain treated though camrelizumab plus lenvatinib therapy with a complete response (CR). By the time of writing, he has had a progression-free survival of 17.5 months and did not experience any severe side effects related to this therapy. Camrelizumab plus lenvatinib therapy showed favorable efficacy and manageable toxicity for this patient with advanced iCCA and could be of interest for more prospective randomized trials to further verify the potential clinical benefits. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382583/ /pubmed/35992782 http://dx.doi.org/10.3389/fonc.2022.911202 Text en Copyright © 2022 Xie, Guo, Zhang, Xu, Song, Shi, Ye, Li and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xie, Peiyi Guo, Lei Zhang, Bo Xu, Yongfeng Song, Qi Shi, Hongcheng Ye, Qinghai Li, Hui Xiao, Yongsheng Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
title | Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
title_full | Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
title_fullStr | Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
title_full_unstemmed | Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
title_short | Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
title_sort | case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382583/ https://www.ncbi.nlm.nih.gov/pubmed/35992782 http://dx.doi.org/10.3389/fonc.2022.911202 |
work_keys_str_mv | AT xiepeiyi casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT guolei casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT zhangbo casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT xuyongfeng casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT songqi casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT shihongcheng casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT yeqinghai casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT lihui casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview AT xiaoyongsheng casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview |